St. John’s wort extracts are proven for the treatment of depressive disorders. However, some preparations, by inducing CYP3A4 and P-glycoprotein (ABCB1), lower the plasma levels of other drugs and impair their efficacy. These pharmacokinetic interactions are not observed with hyperforinergic extracts. Treatment with such extracts increases the safety of this therapy.